These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36843692)

  • 1. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.
    Memon RA; Raveena Bai B; Simran F; Kumari M; Aisha F; Sai Kiran K; Kakarlapudi Y; Saleem F
    Cureus; 2023 Jan; 15(1):e34134. PubMed ID: 36843692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
    Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
    Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
    Rao S; Jamal Siddiqi T; Khan MS; Michos ED; Navar AM; Wang TJ; Greene SJ; Prabhakaran D; Khera A; Pandey A
    Prog Cardiovasc Dis; 2022; 73():48-55. PubMed ID: 35114251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants.
    Sadeghi M; Askari A; Bostan F; Heidari A; Ghasemi G; Alavi Tabatabaei G; Rafiee H; Karimi R; Roohafza H
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt A):102061. PubMed ID: 37640178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.
    Rivera A; Campos B; Ceolin S; Godoi A; Castanha E; Campello Jorge CA; Cardoso R
    Eur J Prev Cardiol; 2023 Nov; 30(16):1828-1837. PubMed ID: 37490769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose combination therapy for the prevention of cardiovascular disease.
    de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD
    Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
    Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
    Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials.
    Massara P; Zurbau A; Glenn AJ; Chiavaroli L; Khan TA; Viguiliouk E; Mejia SB; Comelli EM; Chen V; Schwab U; Risérus U; Uusitupa M; Aas AM; Hermansen K; Thorsdottir I; Rahelić D; Kahleová H; Salas-Salvadó J; Kendall CWC; Sievenpiper JL
    Diabetologia; 2022 Dec; 65(12):2011-2031. PubMed ID: 36008559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
    Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Barnard S; Perel P; Free C
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.
    Elley CR; Gupta AK; Webster R; Selak V; Jun M; Patel A; Rodgers A; Thom S
    PLoS One; 2012; 7(12):e52145. PubMed ID: 23284906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials.
    Mohamed MG; Osman M; Kheiri B; Saleem M; Lacasse A; Alkhouli M
    Int J Cardiol; 2022 Aug; 360():91-98. PubMed ID: 35641323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis on the Clinical Outcomes With Polypills for Cardiovascular Disease Prevention.
    Sedhom R; Hamed M; Tan W; Mansoor H; Stoletniy L; Mamas M; Abramov D; Elgendy IY; Elbadawi A
    Am J Cardiol; 2023 Aug; 201():211-218. PubMed ID: 37385176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Fixed-Dose Combination Therapy (Polypill) Versus Exercise to Improve the Blood-Lipid Profile: A Network Meta-analysis.
    Martínez-Vizcaíno V; Amaro-Gahete FJ; Fernández-Rodríguez R; Garrido-Miguel M; Cavero-Redondo I; Pozuelo-Carrascosa DP
    Sports Med; 2022 May; 52(5):1161-1173. PubMed ID: 34878638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
    Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011094. PubMed ID: 30488422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.